Evidence map›Paper›PMID 37341786›Full record

ArticleArchivum immunologiae et therapiae experimentalis2023

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?

Azza Salamony, Yara Shamikh, Khaled Amer, Tarek Elnagdy, Mostafa Elnakib, Abd Allah Yehia, Wael Hassan, Maha Abdelsalam

Open access · hybridAbstract read
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Azza SalamonyEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.ORCID http://orcid.org/0000-0003-4606-2779
Yara ShamikhEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.ORCID http://orcid.org/0000-0001-7535-459X
Khaled AmerEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.ORCID http://orcid.org/0000-0001-6896-9449
Tarek ElnagdyEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.
Mostafa ElnakibEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.
Abd Allah YehiaEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.
Wael HassanEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt.ORCID http://orcid.org/0000-0001-5998-9106
Maha AbdelsalamEgypt Centre for Research and Regenerative Medicine, ECRRM, Cairo, 11517, Egypt. maha_salama8168@mans.edu.eg.ORCID http://orcid.org/0000-0002-8160-8960
Egypt Center for Research and Regenerative Medicine · EGMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many factors have been implicated in the pathogenesis and severity of COVID-19 pandemic. A wide variation in the susceptibility for SARS-CoV-2 infection among different population, gender and age has been observed. Multiple studies investigated the relationship between the antibody's titre of previously vaccinated individuals and the susceptibility of coronavirus infection, to find a rapid effective therapy for this pandemic. This study focused on the association between measles-mumps-rubella (MMR) antibodies titre and the severity of COVID-19 infection. We aimed to investigate the correlation between the antibody's titre of MMR and the SARS-CoV-2 infection susceptibility and disease severity, in a cohort of COVID-19 Egyptian patients, compared to a control group. MMR antibody titre was measured using enzyme Linked Immune Sorbent Assay; (ELISA) for 136 COVID-19 patients and 44 healthy individuals, as control group. There were high levels of measles and mumps antibodies titer in the deteriorating cases, which could not protect from SARS-CoV-2 infection. However, the rubella antibodies might protect from SARS-CoV-2 infection, but once the infection occurs, it may aggravate the risk of case deterioration. MMR antibodies could be used as a guideline for COVID-19 symptom-severity and, in turn, may be considered as an economic prognostic marker used for early protection from multiple autoimmune organ failure.

Indexed as

COVID-19MeaslesMumpsRubellaHumansMeasles-Mumps-Rubella VaccinePandemicsSARS-CoV-2Measles-Mumps-Rubella VaccineAntibodies titreCOVID-19ELISAMMR

Identifiers

PMID37341786
PMCPMC10284972
OpenAlexW4381469910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.